A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations

Lung cancer (Amsterdam, Netherlands)（2023）

引用 0|浏览13

暂无评分

摘要

•Bevacizumab did not improve PFS of EGFR mutated NSCLC patients receiving afatinib.•Proteinuria was frequently observed and bevacizumab was discontinued in many patients.•In the group receiving both afatinib and bevacizumab, no adverse events of grade 4 or higher were recorded.•Pneumonitis was observed infrequently in both groups.

查看译文

关键词

NSCLC,EGFR,TKI,PFS,OS,ECOG PS,ORR,TTF,AE,CI,HR,SD

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要